NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update.
Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million, an increase of 148% compared to the prior fiscal year. As of June 30, 2024, the Company had $6.30 million in cash.
“Our fiscal 2024 results reflect the dedication we have invested as a team to really drive the business forward,” said Harry Simeonidis, President and CEO at INBS. “Customer demand has remained strong, with orders increasing across the board as more businesses turn to our drug screening technology to safeguard their workforce and uphold their reputation for prioritizing safety. Our progress is promising, and we are continuously refining our strategy to ensure sustainable and profitable long-term growth. We remain on track for our planned FDA 510(k) submission in the fourth calendar quarter of this year and look forward to the opportunities this will unlock in 2025.”
In addition, INBS reported a 20% increase in cartridge sales and a 26% increase in reader sales for the fiscal year ended June 30, 2024, compared to the prior fiscal year. With each reader needing a continuous supply of cartridges for testing, recurring revenue from cartridge sales has been a key driver in INBS’ continued growth across its active customer base of more than 400 businesses.
Spiro Sakiris, CFO at INBS, commented, “We closed out fiscal 2024 with strong results. We have ensured revenue growth through concentrated expansion of our footprint, and with over 1,000 readers now installed, we are generating consistent and recurring revenue from cartridge sales. Awareness of our technology is growing, and we are seeing the results. Our next step is strategic geographical expansion, allowing us to enter new markets and further grow our customer network.”
Operational Highlights for Fiscal 2024:
Fourth Quarter and Full Year Ended June 30, 2024, Financial Results
All amounts are expressed in U.S. dollars unless indicated otherwise.
The Company’s revenue increased by 148% to $3.11 million for the fiscal year ended June 30, 2024, compared to $1.26 million for the fiscal year 2023.
The increase in revenue is due to market demand, increasing brand and product awareness, and continued expansion of the Company’s customer base. Throughout fiscal year 2024, the Company launched its Intelligent Fingerprinting Drug Screening System in the APAC region through its subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, adding to its existing commercialization and marketing efforts in the United Kingdom and Europe.
Loss from operations was $10.28 million for the 2024 fiscal year, compared to $12.59 million in the prior fiscal year. This improvement was primarily driven by an increase in revenue of $1.85 million and gross profit of $1.10 million, complemented by a reduction in total operating expenses of $1.53 million. The net loss attributable to INBS for fiscal year 2024 was $10.16 million, compared to $10.63 million in the prior fiscal year. This is mainly due to a fair value gain on the revaluation of financial instrument of $0.18 million in the fiscal year 2024 compared to $2.15 million in the prior fiscal year.
As of June 30, 2024, the Company’s cash and cash equivalents totalled approximately $6.30 million.
Financial Tables to Follow
Intelligent Bio Solutions Inc.
Consolidated Balance Sheets*
| As of June 30, | As of June 30, | |||||||
| 2024 | 2023 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 6,304,098 | $ | 1,537,244 | ||||
| Accounts receivable, net | 429,704 | 293,861 | ||||||
| Inventories, net | 777,537 | 979,907 | ||||||
| Research and development tax incentive receivable | 525,332 | 498,758 | ||||||
| Other current assets | 497,572 | 552,791 | ||||||
| Total current assets | 8,534,243 | 3,862,561 | ||||||
| Property and equipment, net | 565,850 | 690,175 | ||||||
| Operating lease right of use assets | 306,744 | 546,475 | ||||||
| Intangible assets, net | 4,372,026 | 5,255,401 | ||||||
| Total assets | $ | 13,778,863 | $ | 10,354,612 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 1,704,568 | $ | 2,610,028 | ||||
| Current portion of operating lease liabilities | 274,834 | 223,447 | ||||||
| Current portion of deferred grant income | 2,486,668 | 2,338,057 | ||||||
| Current employee benefit liabilities | 469,381 | 358,942 | ||||||
| Current portion of notes payable | 515,282 | 353,211 | ||||||
| Total current liabilities | 5,450,733 | 5,883,685 | ||||||
| Employee benefit liabilities, less current portion | 63,615 | 24,902 | ||||||
| Operating lease liabilities, less current portion | 81,324 | 356,165 | ||||||
| Notes payable, less current portion | - | 402,862 | ||||||
| Total liabilities | 5,595,672 | 6,667,614 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity | ||||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 3,456,000 and 194,200 shares issued and outstanding at June 30, 2024 and 2023, respectively* | 34,557 | 1,942 | ||||||
| Treasury stock, at cost, 116 shares as of June 30, 2024 and 2023, respectively* | (1 | ) | (1 | ) | ||||
| Additional paid-in capital | 60,971,740 | 46,180,112 | ||||||
| Accumulated deficit | (51,964,332 | ) | (41,807,573 | ) | ||||
| Accumulated other comprehensive loss | (712,614 | ) | (575,496 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 8,329,350 | 3,798,984 | ||||||
| Non-controlling interest | (146,159 | ) | (111,986 | ) | ||||
| Total shareholders’ equity | 8,183,191 | 3,686,998 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 13,778,863 | $ | 10,354,612 | ||||
| * | Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the 1-for-12 Reverse Stock Split on January 26, 2024, throughout the consolidated financial statements unless otherwise stated. |
The accompanying notes are an integral part of these consolidated financial statements.
Intelligent Bio Solutions Inc.
Consolidated Statements of Operations and Other Comprehensive Income (Loss)*
| Year ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | $ | 3,111,781 | $ | 1,256,872 | ||||
| Cost of revenue (exclusive of amortization shown separately below) | (1,686,155 | ) | (930,204 | ) | ||||
| Gross profit | 1,425,626 | 326,668 | ||||||
| Other income: | ||||||||
| Government support income | 424,776 | 737,628 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative expenses | (9,258,496 | ) | (8,026,703 | ) | ||||
| Development and regulatory approval expenses | (1,673,806 | ) | (507,424 | ) | ||||
| Depreciation and amortization | (1,201,274 | ) | (966,732 | ) | ||||
| Goodwill impairment | - | (4,158,670 | ) | |||||
| Total operating expenses | (12,133,576 | ) | (13,659,529 | ) | ||||
| Loss from operations | (10,283,174 | ) | (12,595,233 | ) | ||||
| Other income (expense), net: | ||||||||
| Interest expense | (167,140 | ) | (223,534 | ) | ||||
| Realized foreign exchange loss | (1,178 | ) | (9,829 | ) | ||||
| Fair value gain on revaluation of financial instrument | 175,738 | 2,154,365 | ||||||
| Interest income | 84,822 | 9,676 | ||||||
| Total other income, net | 92,242 | 1,930,678 | ||||||
| Net loss | (10,190,932 | ) | (10,664,555 | ) | ||||
| Net loss attributable to non-controlling interest | (34,173 | ) | (32,835 | ) | ||||
| Net loss attributable to Intelligent Bio Solutions Inc. | $ | (10,156,759 | ) | $ | (10,631,720 | ) | ||
| Other comprehensive income (loss), net of tax: | ||||||||
| Foreign currency translation gain/ (loss) | (137,118 | ) | 212,639 | |||||
| Total other comprehensive income (loss) | (137,118 | ) | 212,639 | |||||
| Comprehensive loss | (10,328,050 | ) | (10,451,916 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (34,173 | ) | (32,835 | ) | ||||
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | (10,293,877 | ) | (10,419,081 | ) | ||||
| Net loss per share, basic and diluted* | $ | (6.38 | ) | $ | (127.00 | ) | ||
| Weighted average units outstanding, basic and diluted * | 1,592,746 | 83,717 | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
| * | Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the 1-for-12 Reverse Stock Split on January 26, 2024, throughout the consolidated financial statement unless otherwise stated. |
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.48 |
| Daily Change: | -0.04 -2.63 |
| Daily Volume: | 95,468 |
| Market Cap: | US$4.620M |
November 13, 2024 November 07, 2024 October 29, 2024 October 16, 2024 October 01, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
